Skip to main content
. 2023 Mar 7;13:1104242. doi: 10.3389/fonc.2023.1104242

Figure 3.

Figure 3

Forest plot between different treatment options and ADT monotherapy (or DOC+ADT) in patients with metastatic hormonal-sensitive prostate cancer (A–H). ADT, androgen deprivation treatment; DOC, docetaxel; AAP, abiraterone acetate and prednisone; ENZA, enzalutamide; APA, apalutamide; RT, radiotherapy; DARO, darolutamide; OS, overall survival; PFS, progression free survival; HVD, high volume disease; LVD, low volume disease; Visc., patients with visceral metastasis; AEs, adverse events. The connector line “_” represents combination of different treatment regimens.